We appreciate Dr Kishore's interest in our recently published manuscript. He questioned the use of bevacizumab (1.25 mg/0.05 mL; Avastin; Genentech Inc, San Francisco, California, USA) for the treatment of subfoveal hemorrhage secondary to retinal arterial macroaneurysm and stated that it has limited benefits. We agree that bevacizumab monotherapy could be insufficient for submacular hemorrhage treatment. He noted that in our study, 2 (Patients 10 and 12) out of 4 patients with submacular hemorrhage showed poor visual outcomes after bevacizuamb injections. However, there were also patients with good visual outcomes in spite of submacular hemorrhage after treatment. In our study, in (Read more...)

Full Story →